From: Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics
Group | N | Sex (M/F) | Age | Histology# |
---|---|---|---|---|
Discovery phase | Â | |||
Gliomas | 5 | 2/3 | 45.20 ± 10.50 | WHO-II (1); WHO-IV (4) |
Validation phase | Â | |||
Gliomas | 10 | 6/4 | 44.78 ± 12.20 | WHO-II (2); WHO-III (2); WHO-IV(6) |
Meningioma | 5 | 2/3 | 54.60 ± 9.42 | -- |
Moyamoya | 6 | 3/3 | 37.67 ± 9.69 | -- |
Healthy control | 12 | 5/7 | 42.17 ± 8.42 | -- |